Armis-Capital, LLC has officially disclosed a significant position in Curis, Inc., signaling a notable shift in the company’s ownership structure. According to a recently filed Schedule 13G, the firm, through its managing member Steven Boyd, has acquired a stake exceeding five percent of Curis, Inc.’s common stock.

The filing specifies that Armis-Capital, LLC holds 372,000 shares, which constitutes 5.57% of the company’s issued share class. While the investment is managed under an agreement that delegates voting rights to Armis-Capital, the documentation clarifies that the shares were acquired in the ordinary course of business. Crucially, the filing indicates that these holdings are not intended to exert control over the biotechnology firm.

For Curis, Inc., a Nasdaq-listed entity specializing in the development of therapeutics for tissue and organ regeneration, this institutional movement comes amidst a period of significant valuation volatility. The company’s stock has seen a dramatic range over the past year, climbing from a 52-week low of $0.33 in October 2026 to a high of $28.40 in December 2025. As of the close on November 16, 2026, the stock was trading at $0.54, with a market capitalization of $1,790,000.

While the current price-to-earnings ratio stands at -0.04, the entry of a major stakeholder like Armis-Capital suggests a level of institutional interest in Curis’s ongoing efforts to advance its oncology drug candidates. At this juncture, no further changes to the ownership position or additional corporate disclosures have been indicated, leaving the market to weigh the implications of this strategic accumulation against the company’s current clinical and financial trajectory.